Amgen Inc. has acquired closely held human genetics firm deCODE genetics EHF for $415mm in cash. (Dec.)
DeCODE was formed in 1996 and brought in about $18mm through venture rounds before it went public in 2000, netting...
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.
Amgen Inc. has acquired closely held human genetics firm deCODE genetics EHF for $415mm in cash. (Dec.)
DeCODE was formed in 1996 and brought in about $18mm through venture rounds before it went public in 2000, netting...
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.